Брой 1/2024, Статии

Thrombophilia and Henoch-Schonlein Purpura in a Child – Clinical Case with Cardiovascular and Pulmonary Manifestations

Публикувана на от admin

A. Dasheva-Dimitrova, N. Kolarova-Yaneva

Pediatric Hospital “Prof. Ivan Mitev”, Sofia, Clinic of Rheumatology and Cardiology

Abstract

  We present a case of a 16-year-old boy with an initial presentation of Henoch-Schonlein purpura and complications such as phlebothrombosis of the right leg, thrombosis of a.dorsalis pedis on the left, a large thrombus in the right ventricle, pulmonary thromboembolism and proven heterozygous carrier of the genetic mutation Factor V Leiden R506Q.

  A brief literature review was made, looking at the relationship between the pathogenetic mechanisms of the diseases and the clinical experience of European medical centers, with the aim of searching for an individual approach in therapeutic behavior.

Key words: Factor V Leiden mutation, Henoch-Schönlein purpura, arterial and venous thrombosis, right ventricular thrombosis, pulmonary thromboembolism

To access this content, you must purchase Годишен абонамент.

Bibliography

  1. А. Телчарова. Васкулитни синдроми у децата.  В: Съвременни проблеми на педиатрията, 1998, 68-92.
  2. Carmichael P., Brun  E., Jayawardene S., et al.   A fatal case of bowel and cardiac involvement in Henoch-Schönlein purpura. Nephrol Dial Transplant. 2002;17:497–499. 
  3. Whitworth H., Clark H.H., Hubbard  R., et al.  High rate of recurrent venous thromboembolism in children and adolescents with unprovoked venous thromboembolism. Journal of . Thromb Haemost. 2023;21: 47-56.
  4. Yılmaz N., Yüksel S., Becerir T., et al.   Myocarditis and intracardiac thrombus due to Henoch-Schönlein purpura: case report and literature review. Clinic rheumatol. 2021;40(4):1635–1644.
  5. Van Langevelde К.,  Flinterman L.E., Van Hylckama A.V., et al.  Broadening the Factor V Leiden Paradox: Pulmonary Embolism and Multisystemic Arterial Thrombosis as 2 Sides of the Spectrum. Blood Adv. 2012;120 (5): 933–946.
  6. Desmarais S., De Moerloose P., Reber G.,  et al.  Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet. 1996; 347 9012:1374 -1375.
  7. Anderson F.A., Wheeler H.B., Goldberg R.J., et al.  A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med.1991;151 (5): 933 -938.
  8. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group: Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000; 83 (5): 657-660.
  9. Silverstein M., Heit J.A., Mohr D.N., et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study.  Arch Intern Med.1998;158 (6): 585 -593.
  10. Van Stralen K.J., Doggen C.J.M., Bezemer I.D., et al. Mechanisms of the factor V Leiden paradox., Arterioscler Thromb Vasc Biol. 2008; 28 10:1872 -1877.
  11. Witmer C., Raffini L. Treatment of venous thromboembolism in pediatric patients. Blood.2020;135:335-343.
  12. Van Ommen C.H,  Heijboer H., Büller H.R. et al. Venous thromboembolism in childhood: a prospective two-year registry in the Netherlands.J Pediatr.2001;139: 676-681.
  13. Tritschler T., Kraaijpoel N., Le Gal G. , Wells P.S. Venous thromboembolism: advances in diagnosis and treatment. JAMA. 2018; 320:1583-1594.
  14. Khan F., Rahman A., Carrier M., et al.  Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019;366: l4363.
  15. Ortel T.L. ,  Neumann I. , Ageno W. , et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism : treatment of deep vein thrombosis and pulmonary embolism. Blood Adv.2020; 4:4693-4738.
  16. Monagle P., Cuello C.A., Augustine C. , et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv. 2018; 2 :3292-3316.
  17. Zaidi M., Singh N., Kamran M., et al. Acute onset of hematuria and proteinuria associated with multiorgan involvement of the heart, liver, pancreas, kidneys and skin in a patient with Henoch-Schönlein purpura. Kidney Int. 2008;73:503–508.
  18. Abdel-Hadi O., Greenstone M.A., Hartley R.B., Kidner P.H. Myocardial infarction – a rare complication in Henoch Schönlein purpura. Postgrad Med J. 1981;57:390–392.
  19. Satoh M., Mikuniya A., Mikami M., et al.  A case of Schönlein-Henoch purpura with myocardial complications. Kokyu To Junkan. 1991;39:273–277. 
  20. O’Greenstone M.A., Hartley R.B., Kidner P.H. Myocardial infarction—a rare complication in Henoch Schönlein purpura. Postgrad Med J. 1981;57:390–392.
  21. Efrat Dagan, Riva Brik, Yiphtah Broza, Ruth Gershoni-Baruch. Henoch–Schonlein purpura: polymorphisms in thrombophilia genes. Pediatr Nephrol. 2006; 21:1117–1121.

Address for correspondence:

Pediatric Hospital “Prof. Ivan Mitev”, Sofia,

Clinic of Rheumatology and Cardiology

11, “Acad. Iv. Geshov”, Blvd.

1606, Sofia

Bulgaria

e-mail: dasheva.anna@gmail.com